<p>Portside Wealth Group LLC 在最近向證券交易委員會（SEC）披露的文件中表示，在第四季度將其在雅培（NYSE:ABT - 免費報告）股票中的持股比例削減了 41.8%。該機構投資者在該季度出售了 13,652 股後，持有 19,016 股這家醫療產品製造商的股票。根據其最近的 SEC 文件，Portside Wealth Group LLC 在雅培的持股價值為 2,382,000 美元。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>AbbVie 的前景：二月份的下跌看起來像是買入信號</li>
</ul>
<p>其他幾家機構投資者和對沖基金最近也調整了對 ABT 的持股。Lakeshore Capital Group Inc. 在第四季度將其在雅培的持股增加了 4.0%。Lakeshore Capital Group Inc. 目前擁有 7,367 股這家醫療產品製造商的股票，價值 923,000 美元，此前在上個季度又增持了 280 股。Sound Income Strategies LLC 在第四季度將其在雅培的持股增加了 6.8%。Sound Income Strategies LLC 目前擁有 2,130 股這家醫療產品製造商的股票，價值 259,000 美元，此前在上個季度又增持了 135 股。Rathbones Group PLC 在第四季度將其在雅培的持股增加了 3.6%。Rathbones Group PLC 目前擁有 3,116,386 股這家醫療產品製造商的股票，價值 390,452,000 美元，此前在上個季度又增持了 107,648 股。Guild Investment Management Inc. 在第四季度購買了雅培的新股份，價值約 202,000 美元。最後，Buffalo Business &amp; Estate Services Ltd. 在第四季度購買了雅培的新股份，價值約 280,000 美元。目前，75.18% 的股票由機構投資者持有。</p>
<h2>分析師設定新目標價</h2>
<p>幾位股票研究分析師最近對 ABT 股票進行了評估。Piper Sandler 在 1 月 23 日的研究報告中將雅培的目標價從 150.00 美元下調至 135.00 美元，並對該公司給予了 “增持” 評級。花旗集團在 3 月 11 日的報告中將雅培的目標價從 140.00 美元下調至 136.00 美元，並對該公司給予了 “買入” 評級。加拿大皇家銀行在 1 月 23 日的報告中將雅培的目標價從 147.00 美元下調至 135.00 美元，並對該公司給予了 “跑贏大盤” 評級。Weiss Ratings 在 1 月 26 日的報告中將雅培的評級從 “買入（b-）” 下調至 “持有（c+）”。最後，Oppenheimer 在 1 月 23 日的報告中將雅培的目標價從 140.00 美元下調至 132.00 美元，並對該公司給予了 “跑贏大盤” 評級。兩位投資分析師對該股票給予了強烈買入評級，十五位給予了買入評級，四位給予了持有評級。根據 MarketBeat.com 的數據，雅培目前的平均評級為 “適度買入”，平均目標價為 135.68 美元。</p>
<ul>
<li>雅培一月份的回調是否是一個好的買入時機？</li>
</ul>
<p><strong>閲讀我們對 ABT 的最新分析</strong></p>
<h2>雅培股票表現</h2>
<p>ABT 的股票在週二開盤價為 102.30 美元。該公司的債務與股本比率為 0.19，流動比率為 1.58，速動比率為 1.18。雅培的股價在一年內最低為 100.88 美元，最高為 139.06 美元。該公司的市值為 1781.6 億美元，市盈率為 27.50，市盈增長比率為 1.64，貝塔值為 0.79。該公司的 50 日移動平均線為 109.35 美元，200 日移動平均線為 120.71 美元。</p>
<ul>
<li>2 家醫療公司可能會因盈利而獲得大幅提升</li>
</ul>
<p>雅培（NYSE:ABT - 獲取免費報告）最近在 1 月 22 日宣佈了其財報。該醫療產品製造商報告每股收益（EPS）為 1.50 美元，符合市場共識預期的 1.50 美元。該公司在本季度的收入為 114.6 億美元，而分析師預期為 118 億美元。雅培的股本回報率為 17.73%，淨利潤率為 14.72%。該公司的季度收入同比增長 4.4%。在去年同期，該公司每股收益為 1.34 美元。雅培已將其 2026 年第一季度的指導目標設定為 1.120-1.180 EPS，2026 財年的指導目標設定為 5.550-5.800 EPS。整體來看，賣方分析師預計雅培在當前年度將發佈 5.14 EPS。</p>
<h2>雅培宣佈分紅</h2>
<p>該公司最近還宣佈了一項季度分紅，將於 5 月 15 日（星期五）支付。4 月 15 日（星期三）登記在冊的股東將獲得 0.63 美元的分紅。這相當於每年 2.52 美元的分紅，收益率為 2.5%。該分紅的除息日期為 4 月 15 日（星期三）。雅培的分紅支付比率（DPR）目前為 67.74%。</p>
<h2>內部人士下注</h2>
<p>在其他新聞中，執行副總裁 Daniel Gesua Sive Salvadori 於 3 月 2 日星期一出售了 885 股公司的股票。股票以平均價格 115.58 美元出售，總交易額為 102,288.30 美元。出售完成後，這位執行副總裁持有 146,377 股公司的股票，價值 16,918,253.66 美元。此次交易使其持股減少了 0.60%。該出售在向 SEC 的法律文件中披露，相關信息可通過此鏈接獲取。此外，副總裁 John A. Jr. Mccoy 於 3 月 2 日星期一出售了 585 股公司的股票。股票以平均價格 115.58 美元出售，總交易額為 67,614.30 美元。出售後，這位副總裁直接持有 24,628 股公司的股票，價值約為 2,846,504.24 美元。此次交易使其持股減少了 2.32%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去三個月中，內部人士出售了 3,055 股公司股票，價值 353,097 美元。目前公司內部人士持有 0.46% 的股票。</p>
<h2>雅培公司簡介</h2>
<p>（免費報告）</p>
<p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的阿博特公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
<p>在診斷方面，雅培提供實驗室和現場檢測平台及試劑，用於檢測傳染病、慢性疾病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過雅培</li>
</ul>
<p><strong>想知道其他對 ABT 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而雅培不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

標普全球醫療股指數 ETF - iShares

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

醫療業 ETF - Vanguard

醫療業 ETF - SPDR

美國制藥 ETF - iShares

雅培

<p>Portside Wealth Group LLC 在第四季度減少了對雅培（NYSE:ABT）的持股比例，下降了 41.8%，出售了 13,652 股，剩餘 19,016 股，價值 238 萬美元。其他機構投資者也調整了他們的持股。分析師們下調了雅培的目標股價，平均目標為 135.68 美元。雅培的股票開盤價為 102.30 美元，市值為 1781.6 億美元。該公司報告第四季度每股收益為 1.50 美元，符合預期，並宣佈將於 5 月 15 日支付季度股息</p>

<p>Portside Wealth Group LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 41.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,016 shares of the healthcare product maker's stock after selling 13,652 shares during the quarter. Portside Wealth Group LLC's holdings in Abbott Laboratories were worth $2,382,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Portside Wealth Group LLC 在最近向證券交易委員會（SEC）披露的文件中表示，在第四季度將其在雅培（NYSE:ABT - 免費報告）股票中的持股比例削減了 41.8%。該機構投資者在該季度出售了 13,652 股後，持有 19,016 股這家醫療產品製造商的股票。根據其最近的 SEC 文件，Portside Wealth Group LLC 在雅培的持股價值為 2,382,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 的前景：二月份的下跌看起來像是買入信號</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of ABT. Lakeshore Capital Group Inc. increased its position in shares of Abbott Laboratories by 4.0% during the fourth quarter. Lakeshore Capital Group Inc. now owns 7,367 shares of the healthcare product maker's stock valued at $923,000 after acquiring an additional 280 shares in the last quarter. Sound Income Strategies LLC increased its position in shares of Abbott Laboratories by 6.8% during the fourth quarter. Sound Income Strategies LLC now owns 2,130 shares of the healthcare product maker's stock valued at $259,000 after acquiring an additional 135 shares in the last quarter. Rathbones Group PLC increased its position in shares of Abbott Laboratories by 3.6% during the fourth quarter. Rathbones Group PLC now owns 3,116,386 shares of the healthcare product maker's stock valued at $390,452,000 after acquiring an additional 107,648 shares in the last quarter. Guild Investment Management Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $202,000. Finally, Buffalo Business &amp; Estate Services Ltd. bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $280,000. 75.18% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也調整了對 ABT 的持股。Lakeshore Capital Group Inc. 在第四季度將其在雅培的持股增加了 4.0%。Lakeshore Capital Group Inc. 目前擁有 7,367 股這家醫療產品製造商的股票，價值 923,000 美元，此前在上個季度又增持了 280 股。Sound Income Strategies LLC 在第四季度將其在雅培的持股增加了 6.8%。Sound Income Strategies LLC 目前擁有 2,130 股這家醫療產品製造商的股票，價值 259,000 美元，此前在上個季度又增持了 135 股。Rathbones Group PLC 在第四季度將其在雅培的持股增加了 3.6%。Rathbones Group PLC 目前擁有 3,116,386 股這家醫療產品製造商的股票，價值 390,452,000 美元，此前在上個季度又增持了 107,648 股。Guild Investment Management Inc. 在第四季度購買了雅培的新股份，價值約 202,000 美元。最後，Buffalo Business &amp; Estate Services Ltd. 在第四季度購買了雅培的新股份，價值約 280,000 美元。目前，75.18% 的股票由機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several equities research analysts recently weighed in on ABT shares. Piper Sandler reduced their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an &#34;overweight&#34; rating for the company in a research report on Friday, January 23rd. Citigroup reduced their price objective on Abbott Laboratories from $140.00 to $136.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, March 11th. Royal Bank Of Canada reduced their price objective on Abbott Laboratories from $147.00 to $135.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, January 23rd. Weiss Ratings downgraded Abbott Laboratories from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a report on Monday, January 26th. Finally, Oppenheimer reduced their price objective on Abbott Laboratories from $140.00 to $132.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $135.68.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對 ABT 股票進行了評估。Piper Sandler 在 1 月 23 日的研究報告中將雅培的目標價從 150.00 美元下調至 135.00 美元，並對該公司給予了 “增持” 評級。花旗集團在 3 月 11 日的報告中將雅培的目標價從 140.00 美元下調至 136.00 美元，並對該公司給予了 “買入” 評級。加拿大皇家銀行在 1 月 23 日的報告中將雅培的目標價從 147.00 美元下調至 135.00 美元，並對該公司給予了 “跑贏大盤” 評級。Weiss Ratings 在 1 月 26 日的報告中將雅培的評級從 “買入（b-）” 下調至 “持有（c+）”。最後，Oppenheimer 在 1 月 23 日的報告中將雅培的目標價從 140.00 美元下調至 132.00 美元，並對該公司給予了 “跑贏大盤” 評級。兩位投資分析師對該股票給予了強烈買入評級，十五位給予了買入評級，四位給予了持有評級。根據 MarketBeat.com 的數據，雅培目前的平均評級為 “適度買入”，平均目標價為 135.68 美元。</p>
</div><ul>
<li>Is Abbott’s January Pullback a Good Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培一月份的回調是否是一個好的買入時機？</li>
</ul>
</div><p><strong>Read Our Latest Analysis on ABT</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 ABT 的最新分析</strong></p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表現</h2>
</div><p>Shares of ABT opened at $102.30 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a one year low of $100.88 and a one year high of $139.06. The firm has a market capitalization of $178.16 billion, a P/E ratio of 27.50, a PEG ratio of 1.64 and a beta of 0.79. The business has a fifty day moving average of $109.35 and a 200 day moving average of $120.71.</p>
<div class="lb-trans"><p>ABT 的股票在週二開盤價為 102.30 美元。該公司的債務與股本比率為 0.19，流動比率為 1.58，速動比率為 1.18。雅培的股價在一年內最低為 100.88 美元，最高為 139.06 美元。該公司的市值為 1781.6 億美元，市盈率為 27.50，市盈增長比率為 1.64，貝塔值為 0.79。該公司的 50 日移動平均線為 109.35 美元，200 日移動平均線為 120.71 美元。</p>
</div><ul>
<li>2 Healthcare Names That Could Get a Big Boost From Earnings</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家醫療公司可能會因盈利而獲得大幅提升</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analysts' expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business's revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近在 1 月 22 日宣佈了其財報。該醫療產品製造商報告每股收益（EPS）為 1.50 美元，符合市場共識預期的 1.50 美元。該公司在本季度的收入為 114.6 億美元，而分析師預期為 118 億美元。雅培的股本回報率為 17.73%，淨利潤率為 14.72%。該公司的季度收入同比增長 4.4%。在去年同期，該公司每股收益為 1.34 美元。雅培已將其 2026 年第一季度的指導目標設定為 1.120-1.180 EPS，2026 財年的指導目標設定為 5.550-5.800 EPS。整體來看，賣方分析師預計雅培在當前年度將發佈 5.14 EPS。</p>
</div><h2>Abbott Laboratories Announces Dividend</h2>
<div class="lb-trans"><h2>雅培宣佈分紅</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 67.74%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，將於 5 月 15 日（星期五）支付。4 月 15 日（星期三）登記在冊的股東將獲得 0.63 美元的分紅。這相當於每年 2.52 美元的分紅，收益率為 2.5%。該分紅的除息日期為 4 月 15 日（星期三）。雅培的分紅支付比率（DPR）目前為 67.74%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares of the company's stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP John A. Jr. Mccoy sold 585 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president directly owned 24,628 shares of the company's stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新聞中，執行副總裁 Daniel Gesua Sive Salvadori 於 3 月 2 日星期一出售了 885 股公司的股票。股票以平均價格 115.58 美元出售，總交易額為 102,288.30 美元。出售完成後，這位執行副總裁持有 146,377 股公司的股票，價值 16,918,253.66 美元。此次交易使其持股減少了 0.60%。該出售在向 SEC 的法律文件中披露，相關信息可通過此鏈接獲取。此外，副總裁 John A. Jr. Mccoy 於 3 月 2 日星期一出售了 585 股公司的股票。股票以平均價格 115.58 美元出售，總交易額為 67,614.30 美元。出售後，這位副總裁直接持有 24,628 股公司的股票，價值約為 2,846,504.24 美元。此次交易使其持股減少了 2.32%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去三個月中，內部人士出售了 3,055 股公司股票，價值 353,097 美元。目前公司內部人士持有 0.46% 的股票。</p>
</div><h2>Abbott Laboratories Company Profile</h2>
<div class="lb-trans"><h2>雅培公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的阿博特公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在診斷方面，雅培提供實驗室和現場檢測平台及試劑，用於檢測傳染病、慢性疾病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過雅培</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 ABT 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而雅培不在名單上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Portside Wealth Group LLC 出售雅培實驗室 13,652 股股份 $ABT